Onkologie. 2011:5(4):226-229

Multidisciplinary approach in the therapy of gastrointestinal stromal tumors

Bohuslav Melichar, Michaela Zezulová, Hana Procházková-Študentová
Onkologická klinika LF UP a FN Olomouc

The therapy of gastrointestinal stromal tumors may serve as an example of success of multidisciplinary approach in the therapy of

malignant disorders. A significant progress in the therapy of metastatic GIST was obtained with the use of molecular targeted therapy

(imatinib). The advent of targeted therapy also resulted in improved possibilities of surgical intervention and imatinib is currently used in

the adjuvant as well as neoadjuvant indication. Close collaboration between surgical and medical oncologist as well as the concentration

of patients with this rare tumor to specialized centers are of fundamental importance for optimal therapy and outcome.

Keywords: gastrointestinal stromal tumor, imatinib, sunitinib

Published: December 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Melichar B, Zezulová M, Procházková-Študentová H. Multidisciplinary approach in the therapy of gastrointestinal stromal tumors. Onkologie. 2011;5(4):226-229.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. DeMatteo RP, Heinrich MC, El-Rifai WM, Demetri G. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Human Pathol 2002; 33: 466-477. Go to original source... Go to PubMed...
    2. Crosby JA, Catton CN, Davis A, Couture J, O'Sullivan B, Kandel R, Swallow CJ. Malignant gastrointestinal stromal tumors of the small intestine: a review of 50 cases from a prospective database. Ann Surg Oncol 2001; 8: 50-59. Go to original source... Go to PubMed...
    3. Tuveson DA, Willis NA, Jacks T, Griffin JD, Singer S, Fletcher CDM, Fletcher JA, Demetri GD. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 2001; 20: 5054-5058. Go to original source... Go to PubMed...
    4. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004; 22: 3813-3825. Go to original source... Go to PubMed...
    5. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CDM, Silberman S, Dimitrijevic S, Fletcher JA. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21: 4342-4349. Go to original source... Go to PubMed...
    6. Demetri GD, von Mehren M, Blanke CD, van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CDM, Joensuu H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-480. Go to original source... Go to PubMed...
    7. van Oosterom AT, Judson I, Verweij J, Stroobants S, di Paola ED, Dimitrijevic S, Martens M, Webb A, Sciot R, Van Glabbeke M, Silberman S, Nielsen OS. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001; 358: 1421-1423. Go to original source... Go to PubMed...
    8. Reichardt P, Schneider U, Stroszczynski C, Pink D, Hohenberger P. Molecular response of gastrointestinal stromal tumour after treatment with tyrosine kinase inhibitor imatinib mesylate. J Clin Pathol 2004; 57: 215-217. Go to original source... Go to PubMed...
    9. Melichar B, Laco J, Slovacek L, Grossmann P, Vanecek T. Fatal venous thrombembolism complicating imatinib therapy in a patient with metastatic gastrointestinal stromal tumor. J Exp Clin Cancer Res 2006; 25: 607-610.
    10. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, Issels R, van Oosterom A, Hogendoorn PCW, Van Glabbeke M, Bertulli R, Judson I. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004; 364: 1127-1134. Go to original source... Go to PubMed...
    11. Wu PC, Langerman A, Ryan CW, Hart J, Swiger S, Posner MC. Surgical treatment of gastrointestinal stromal tumors in the imatinib (STI-571) era. Surgery 2003; 134: 656-666. Go to original source... Go to PubMed...
    12. Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, Corless CL, Fletcher CDM, Roberts PJ, Heinz D, Wehre E, Nikolova Z, Joensuu H. Long-term results from a randomized phase II trial of standard-versus higherdose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008; 26: 620-625. Go to original source... Go to PubMed...
    13. Ng EH, Pollock RE, Romsdahl MM. Prognostic implications of patterns of failure for gastrointestinal leiomyosarcomas. Cancer 1992; 69: 1334-1341. Go to original source...
    14. Ng EH, Pollock RE, Munsell MF, Atkinson EN, Romsdahl MM. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann Surg 1992; 215: 68-77. Go to original source... Go to PubMed...
    15. Pietras K, Ostman A, Sjoquist M, Buchdunger E, Reed RK, Heldin CH, Rubin K. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 2001; 61: 2929-2934.
    16. Demetri GD, Van OOsterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368: 1329-1338. Go to original source... Go to PubMed...
    17. de Matteo RP, Ballman CR, Antonescu CR, Maki RG, Pisters PWT, Demetri GD, Blackstein ME, Blanke CD, von Mehren M, Brennan MF, Patel S, McCarter MD, Polikoff JA, Tan BR, Owzar K. Adjuvant imatinib mesylate resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009; 373: 1097-1104. Go to original source... Go to PubMed...
    18. Fraker DL, Soulen M. Regional therapy of hepatic metastases. Hem Oncol Clin N Am 2002; 16: 947-967. Go to original source... Go to PubMed...
    19. Berney T, Mentha G, Roth AD, Morel P. Results of surgical resection of liver metastases from non-colorectal primaries. Br J Surg 1998; 85: 1423-1427. Go to original source... Go to PubMed...
    20. Tepetes K, Tsamandas AC, Ravazoula P, Petsas T, Bonikos DS, Karavias DD. Survival for 5 years after repeat liver resections and multimodality treatment for metastatic intestinal leiomyosarcoma: report of a case. Surg Today 2002; 32: 925-928. Go to original source... Go to PubMed...
    21. Curley SA, Izzo F, Delrio P, Ellis LM, Granchi J, Vallone P, Flore F, Pignata S, Daniele B, Cremona F. Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies. Results in 123 patients. Ann Surg 1999; 230: 1-8. Go to original source... Go to PubMed...
    22. Curley SA, Marra P, Beaty K, Ellis LM, Vauthey JN, Abdalla EK, Scaife C, Raut C, Wolff R, Choi H, Loyer E, Vallone P, Fiore F, Scordino F, De Rosa V, Orlando R, Pignata S, Daniele B, Izzo F. Early and late complications after radiofrequency ablation of malignant liver tumors in 608 patients. Ann Surg 2004; 239: 450-458. Go to original source... Go to PubMed...
    23. Siperstein A, Garland A, Engle K, Rogers S, Berber E, Foroutani A, String A, Ryan T, Ituarte P. Local recurrence after laparoscopic radiofrequency thermal ablation of hepatic tumors. Ann Surg Oncol 2000; 7: 106-113. Go to original source... Go to PubMed...
    24. Bumming P, Andersson J, Meis-Kindblom JM, Klingestierna H, Engstrom K, Stierner U, Wangberg B, Jansson S, Ahlman H, Kindblom LG, Nilsson B. Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumors (GIST) with imatinib: a centre-based study of 17 patients. Br J Cancer 2003; 89: 460-464. Go to original source... Go to PubMed...
    25. Scaife CL, Hunt KK, Patel SR, Benjamin RS, Burgess MA, Chen LL, Trent J, Raymon AK, Cormier JN, Pisters PWT, Pollock RE, Feig BW. Is there a role for surgery in patients with, ,unresectable" cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate? Am J Surg 2003; 186: 665-669. Go to original source... Go to PubMed...
    26. Okamoto K, Muguruma N, Aoki R, Sato Y, Nakamoto J, Imoto Y, Okamura S, Ito S, Okitsu H, Sano T. A treatment using STI571 for jejunal gastrointestinal stromal tumor (GIST) accompanied with liver metastasis and peritoneal dissemination. Intern Med 2004; 43: 1151-1156. Go to original source... Go to PubMed...
    27. Eisenberg BL, Judson I. Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy. Ann Surg Oncol 2004; 11: 465-475. Go to original source... Go to PubMed...
    28. Melichar B, Voboril Z, Nozicka J, Ryska A, Urminska H, Vanecek T, Michal M. Pathological complete response in advanced gastrointestinal stromal tumor after imatinib therapy. Intern Med 2005; 44: 1163-1168. Go to original source... Go to PubMed...
    29. Chacon M, Roca E, Huertas E, Loria FS, Domenechini E. Case 3. Pathologic complete remission of metastatic gastrointestinal stromal tumor after imatinib mesylate. J Clin Oncol 2005; 23: 1580-1582. Go to original source... Go to PubMed...
    30. Mussi C, Ronellenfitsch U, Jakob J, Tamborini E, Reichardt P, Casali PG, Flore M, Hohenberger P, Gronchi A. Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients? Ann Oncol 2010; 21: 403-408. Go to original source... Go to PubMed...
    31. Carson W, Karakousis C, Douglass H, Rao U, Palmer ML. Results of aggressive treatment of gastric sarcoma. Ann Surg Oncol 1994; 1: 244-251. Go to original source... Go to PubMed...
    32. Fiorentini G, Bernardesci P, De Simone M, Rossi S, Dentico P, Biancalani M, Scuderi S, Vaira M, Palomba A. Efficacy of imatinib mesylate in patients with liver metastases from gastrointestinal stromal tumor failing intra-arterial hepatic chemotherapy with epirubicin. J Exp Clin Cancer Res 2003; 22(Suppl): 13-16.
    33. Melichar B, Voboril Z, Nozicka J, Cerman J, Melicharova K, Mergancova J, Filip S, Krajina A, Voboril R, Jandik P. Hepatic arterial infusion chemotherapy in sarcoma liver metastasis: A report of 6 cases. Tumori 2005; 91: 19-23. Go to original source... Go to PubMed...
    34. Matsumoto S, Takeuchi T, Morita S. Transcatheter arterial embolization for cystic hepatic metastases from leiomyosarcoma of gastrointestinal tract (in Japanese). Rinsho Hoshasen 1990; 35: 453-458. Go to PubMed...
    35. Maruo H, Kosaka A. A case of liver metastasis from retroperitoneal leiomyosarcoma successfully treated by intraarterial infusion chemotherapy of adriamycin or epirubicin using an implantable reservoir (in Japanese). Gan To Kagaku Ryoho 1993; 20: 291-294.
    36. Khansur T, Patel V, Newcomb M, Balducci L. Hepatic intra-arterial adriamycin in metastatic leiomyosarcoma: Exploiting the steep dose-response curve. J Surg Oncol 1987; 36: 76-79. Go to original source... Go to PubMed...
    37. Mavligit GM, Zukwiski AA, Ellis LM, Chuang VP, Wallace S. Gastrointestinal leiomyosarcoma metastatic to the liver. Durable tumor regression by hepatic chemoembolization infsuion with cisplatin and vinblastine. Cancer 1995; 75: 2083-2088. Go to original source...
    38. Rajan DJ, Soulen MC, Clark TWI, Baum RA, Haskal ZJ, Shlansky-Goldberg RD, Freiman DB. Sarcomas metastatic to the liver: Response and survival after cisplatin, doxorubicin, mitomycin-C, ethiodol, and polyvinyl alcohol chemoembolization. J Vasc Interv Radiol 2001; 12: 187-193. Go to original source... Go to PubMed...
    39. Miya A, Yasuda S, Morimoto O, Tsuji Y, Shiozaki K, Baba M, Ishida H, Masutani S, Tatsuta M, Kawasaki T, Satomi T. A case of liver metastases of gastric leiomyosarcoma successfully treated by transarterial hepatic chemo-embolization and intra hepato-arterial chemotherapy repeated with infusion-a-port (in Japanese). Gan To Kagaku Ryoho 1997; 24: 1878-1881.
    40. Takayama T, Kato H, Tachimori Y, Watanabe H, Furukawa H, Takayatsu K, Sakamoto M, Makuuchi M. Treatment of rupture of a liver metastasis from esophageal leiomyosarcoma. Jpn J Clin Oncol 1996; 26: 248-251. Go to original source... Go to PubMed...
    41. Mavligit GM, Zukivski AA, Gutterman JU, Salem P, Charnsangavej C, Wallace S. Splenic versus hepatic artery infusion of interleukin-2 in patients with liver metastases. J Clin Oncol 1990; 8: 319-324. Go to original source... Go to PubMed...
    42. Bedikian AY, Mavligit G, Carrasco CR, Legha SS, Benjamin RS. Phase I evaluation of hepatic arterial infusion of interferon-alfa-2b in patients with liver cancer. Reg Cancer Treat 1996; 9: 17-20.
    43. Alexander HR, Barlett DL, Libutti SK, Fraker DL, Moser T, Rosenberg SA. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol 1998; 16: 1479-1489. Go to original source... Go to PubMed...
    44. Hafstrom L, Holmberg SB, Lindner P, Naredi P, Asztely, Bengtsson A, Nielsen HK, Schersten T. Isolated regional liver perfusion with tumour necrosis factor-alpha followed by hyperthermic melphalan perfusion. Reg Cancer Treat 1994; 7: 172-176.
    45. Ravikumar TS, Pizzorno G, Bodden W, Marsh J, Strair R, Pollack J, Hendler R, Hanna J, D'Andrea E. Percutaneous hepatic vein isolation and high-dose hepatic arterial infusion chemotherapy for unresectable liver tumors. J Clin Oncol 1994; 12: 2723-2736. Go to original source... Go to PubMed...
    46. DeMatteo RP, Shah A, Fong Y, Jarnagin WR, Blumgart LH, Brennan MF. Results of hepatic resection for sarcoma metastatic to liver. Ann Surg 2001; 234: 540-548. Go to original source... Go to PubMed...
    47. Lang H, Nussbaum KT, Kaudel P, Fruhauf N, Flemming P, Raab R. Hepatic metastases from leiomyosarcoma. A single-center experience with 34 resections during a 15-year period. Ann Surg 2000; 231: 500-505. Go to original source... Go to PubMed...
    48. Elias D, Cavalcanti de Albuquerque A, Eggenspieler P, Plaud B, Ducreux M, Spielmann M, Theodore C, Bonvalot S, Lasser P. Resection of liver metastases from a noncolorectal primary: Indications and results based on 147 monocentric patients. J Am Coll Surg 1998; 187: 487-493. Go to original source... Go to PubMed...
    49. Chen H, Pruitt A, Nicol TL, Gorgulu S, Choti MA. Complete hepatic resection of metastases from leiomyosarcoma prolongs survival. J Gastrointest Surg 1998; 2: 151-155. Go to original source... Go to PubMed...
    50. Hafner GH, Rao U, Karakousis CP. Liver metastases from soft tissue sarcoma. J Surg Oncol 1995; 58: 12-16. Go to original source... Go to PubMed...
    51. Karavias DD, Tepetes K, Karatzas T, Felekouras E, Androulakis J. Liver resection for metastatic non-colorectal non-endocrine hepatic neoplasms. Eur J Surg Oncol 2002; 28: 135-139. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.